NR4A1 and breast cancer: In stage T1N1M0 women participating in screening who underwent MTX had a HR of 2.91 (95% CI 1.30–6.48) for breast cancer death compared to women who underwent BCT, after adjusting for screening detection, years of diagnosis, age at diagnosis, histology, grade, and hormone receptor status.